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There are no data on the role of postcon-
solidation therapy with gemtuzumab ozo-
gamicin (GO; Mylotarg) in children with
acute myeloid leukemia (AML). The
NOPHO-AML 2004 protocol studied post-
consolidation randomization to GO or no
further therapy. GO was administered at
5 mg/m2 and repeated after 3 weeks. We
randomized 120 patients; 59 to receive
GO. Survival was analyzed on an
intention-to-treat basis. The median
follow-up for patients who were alive was
4.2 years. Children who received GO
showed modest elevation of transami-
nase and bilirubin without signs of veno-
occlusive disease. Severe neutropenia fol-
lowed 95% and febrile neutropenia 40% of
the GO courses. Only a moderate decline
in platelet count and a minor decrease in
hemoglobin occurred. Relapse occurred
in 24 and 25 of those randomized to GO
or no further therapy. The median time to
relapse was 16 months versus 10 months
(nonsignificant). The 5-year event-free
survival and overall survival was 55%
versus 51% and 74% versus 80% in those
randomized to receive GO or no further
therapy, respectively. Results were simi-
lar in all subgroups. In conclusion, GO
therapy postconsolidation as given in
this trial was well tolerated, showed a
nonsignificant delay in time to relapse,
but did not change the rate of relapse or
survival (clinicaltrials.gov identifier
NCT00476541). (Blood. 2012;120(5):
978-984)
Introduction
Improvements in induction and consolidation therapy as well as
supportive care in pediatric acute myeloid leukemia (AML) have
resulted in remission rates above 90% and overall survival (OS)
above 65%.1-4 Despite the progress, approximately one-third of the
patients eventually relapse.
Gemtuzumab ozogamicin (GO; Mylotarg) is a humanized
anti-CD33–calicheamicin conjugate developed for targeted treat-
ment of AML and was approved for use by the US Food and Drug
Administration in 2000 but withdrawn in October 2010 because of
concerns about both toxicity and efficacy in adults. The major side
effects are myelosuppression and liver dysfunction.5 Despite the
withdrawal of GO, studies on the safety and efficacy of GO are
ongoing and continuously published6,7 and the final role of GO in
AML therapy is unsettled.8
There is only limited experience of using GO in children. A phase 1
trial performed by the Children’s Oncology Group (COG) started at a
dose of 9 mg/m2 but was reduced to 6 mg/m2 because of liver toxicity.9
A phase 2 study with GO administered to relapsed AML as 2 doses of
7.5 mg/m2 with a 14-day interval was well tolerated with response rates
of 30%-40%.10,11 GO has been applied during induction in a few
protocols for de novo pediatric AML,2,7,12 demonstrating that the
combination of GO with intensive chemotherapy is safe and feasible but
the benefit of the approach is still unclear.
Postconsolidation GO therapy has been used in elderly AML
patients with variable results. A small study indicated a benefit
from 3 low-dose 3 mg/m2 monthly doses,13 whereas a phase 3 study
using 3 cycles of monthly GO at 6 mg/m2 did not result in any
benefit for the GO-treated group.14 There are no experiences of
postconsolidation GO therapy in children. We report the results of
the Nordic Society of Paediatric Hematology and Oncology
(NOPHO) 2004 protocol including postconsolidation randomiza-
tion to GO or no further therapy.
Methods
The NOPHO-AML 2004 protocol (clinicaltrials.gov identifier
NCT00476541) opened in January 2004 and included all children diag-
nosed with AML in the 5 Nordic countries (Denmark, Finland, Iceland,
Norway, and Sweden); from November 2007, Hong Kong was also
included. NOPHO-AML 2004 included induction with AIET (cytarabine,
idarubicin, etoposide, and 6-thioguanine).3 The second induction course
and the 4 consolidation courses were similar to the NOPHO-AML
93 protocol.15 The flowchart of the protocol is shown in Figure 1. The
cumulated doses were 6-thioguanin 800 mg/m2, cytarabine 49 300 mg/m2,
etoposide 1200 mg/m2, idarubicin 36 mg/m2, and mitoxantrone 60 mg/m2.
High-risk patients, defined as having poor response to induction
( 15% blasts after AIET or no remission after second induction) or the
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presence of MLL rearrangements other than t(9;11)(p21;q23), were offered
hematopoietic stem cell transplantation (HSCT) with a matched sibling or
unrelated donor if a matched donor was identified before the last consolida-
tion. An amendment of the protocol in June 2009 restricted the high-risk
criteria to poor response only. Complete remission (CR) was defined as a
cellular bone marrow with blasts below 5% and neutrophils above
1  109/L and platelets above 100 109/L.
Randomization to GO or no further therapy was offered to standard-risk
patients and high-risk patients in first complete remission (CR1) who
completed consolidation without HSCT because of lack of donor. Random-
ization was balanced according to risk group. Patients were only eligible for
randomization when they had started the last consolidation course (second
HA2E). National ethics committees and institutional review boards in each
country approved the study, and randomization was only done after
obtaining informed consent according to national guidelines following the
Declaration of Helsinki.
GO was administered as a 2-hour infusion of 5 mg/m2 at least 4 weeks
after the last consolidation course and repeated after an interval of 3 weeks.
GO was only given when transaminase levels were less than 5 times the
upper normal limit, bilirubin 20M, neutrophils 1.0  109/L, and
platelets  80  109/L. Antifungal prophylaxis was discontinued during
GO therapy. Premedication with acetaminophen, clemastine (meclastin),
and methylprednisolone was given before GO. Blood samples and clinical
history were obtained at least twice a week for a minimum of 3 weeks after
each of the 2 GO infusions. End points were toxicity of the GO therapy,
relapse rate, and survival in the 2 randomized arms.
Statistical methods
The study was designed with a power of 82% to detect a difference in
relapse rate of 25% by including 120 patients. Interim analyses were
performed annually by the data monitoring committee. The randomization
was closed in December 2010 when 120 patients were randomized. To
compare the distribution of categorical or dichotomized variables, the 2
test was used and the Fisher exact test was used when the expected count in
any cell of the table was 5.
Event-free survival (EFS) was defined as the time from diagnosis until
death in remission, relapse, second malignancy, or last follow-up, whatever
occurred first. OS was defined as the time from diagnosis to death from any
cause or last follow-up. All patients were followed to death or February
2012, 15 months after the last patient was randomized. No patients were
lost to follow-up. The median time of follow-up for patients who were alive
was 4.2 years from diagnosis (range 1.7 to 7.8 years). The probabilities of
Figure 2. Patient flow and randomization in the
NOPHO-AML 2004 protocol. Postconsolidation GO ran-
domization in patients diagnosed from 2004 to 2010.
Figure 1. Flowchart of the NOPHO-AML 2004 protocol. High-risk patients were eligible for HSCT after completing 3 courses but before the last consolidation (HA2E). AIET
indicates cytarabine 200 mg/m2 continuous infusion days 1-4, 6-thioguanine 100 mg/m2 bis in die (bid) days 1-4, etoposide 100 mg/m2 days 1-4, idarubicin 12 mg/m2 days 2, 4,
and 6. AM indicates cytarabine 100 mg/m2 continuous infusion days 1-5, mitoxantrone 10 mg/m2 days 1-3. HA1M indicates cytarabine 1 g/m2 bid days 1-3, mitoxantrone
10 mg/m2 days 3-5. HA2E indicates cytarabine 2 g/m2 bid days 1-3, etoposide 100 mg/m2 days 2-5. HA3 indicates cytarabine 3 g/m2 bid days 1-3. GO indicates gemtuzumab
ozogamicin 5 mg/m2 days 1 and 21.
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EFS and OS were estimated by the Kaplan-Meier method and differences
between survival distributions were compared with the log-rank test.
Results
When the targeted 120 patients were randomized by December
2010, a total of 230 patients had been entered on NOPHO-AML
2004. Randomization had not been offered to 86 patients because
of death (n 14), relapse (n 13), HSCT (n 29), or closure of
the randomization (n 30) before they reached last consolidation.
Participation in the randomization was declined by the parents/
children or the treating physicians in 24 (17%) of the 144 eligible
patients (Figure 2).
The clinical characteristics of the 120 patients randomized are
presented in Table 1. There were no statistically significant
differences between the 2 groups. There was a nonsignificant
excess of patients with white blood cell count (WBC) more than
100 109/L (P  .053) and FLT3-ITD aberration (P  .06) in the
group randomized to no further therapy.
Three of the 59 patients randomized to receive GO withdrew the
acceptance for participation and 3 relapsed before therapy was
completed. One patient randomized to no further therapy received
GO. Analyses were performed on an intention-to-treat basis
according to the result of the randomization.
Toxicity
Detailed toxicity data were available from all 53 patients who
received both GO courses as randomized. The median interval
from last consolidation to GO was 31 days (range 27-50) and the
median interval between first and second GO was 21 days (range
20-41). The interval between first and second GO was more than
4 weeks in 3 patients because of prolonged neutropenia, elevated
transaminase, and shingles. No major events were reported in
relation to the infusions.
The hematologic toxicity is shown in Table 2. Only a minor
decrease in hemoglobin was observed after both GO infusions. No
patients received red cell transfusion. Severe leukopenia, WHO
grade 4, WBC  1.0  109/L was seen in 81% after first GO and in
67% after second GO. Severe neutropenia was almost universal
with a median neutrophil nadir of 0.0 109/L (neutrophils 0.5 in
94%-96% after first and second GO). Neutropenia  0.5  109/L
lasted a median of 15 days (range 0-43) after both GO courses.
Neutrophils  0.5 for more than 20 days was seen in one patient
after the first GO and in 4 patients after the second GO. Febrile
neutropenia treated with antibiotics followed 42 (40%) of the GO
courses (23 episodes [43%] after the first and 19 [36%] after the
second GO). Those with febrile neutropenia after the first course
had a 74% risk of a febrile episode after the second course
compared with only 7% of those without febrile episode after the
first course (P  .001). None of the infectious episodes were
life-threatening (no cases of hypotension or need of intensive care).
A moderate decline in platelet count was noted with median
nadir of 83 109/L after the first GO and 62 109/L after the
second GO. Platelet nadir was  50  109/L in 15% after the first
and in 39% after the second GO (P  .01). Platelet transfusion was
given after 11 (10%) of the GO courses to 9 different patients (17%).
Liver toxicity is shown in Table 2. Alanine aminotransferase
(ALAT) and bilirubin showed only a slight increase from the
baseline values. Moderate elevation of transaminase was common,
whereas only 2 episodes of bilirubin level above 25 mol/L
occurred. None of the patients showed signs of hepatic veno-
occlusive disease (VOD).
Survival
No patients died in CR1 after GO therapy. Therapy-related
myelodysplastic syndrome (t-MDS) developed in 2 patients 1.7 and
3.0 years from AML diagnosis, and 12 and 29 months from GO
therapy. Relapse occurred in 24 patients among those randomized
to GO (including 3 relapses before start of GO) and in 25 of those
randomized to no further therapy. The median time to relapse was
16 months in the GO arm versus 11 months in those receiving no
GO (nonsignificant; Table 3).
Table 1. Characteristics of the 120 patients randomized
Characteristics
Randomized to GO,
N  59, n (%)
Randomized to no
further therapy,
N  61, n (%) P
Sex .30
Male 30 (51) 37 (61)
Female 29 (49) 24 (39)
Age, y .62
0-1 16 (27) 15 (25)
2-9 22 (37) 28 (46)
10 21 (36) 18 (30)
White blood count, 109/L .12
0-9.9 22 (37) 24 (39)
10-99 35 (59) 29 (48)
 100 2 (3) 8 (13)
FAB classification .86
M0 3 (5) 4 (7)
M1 7 (12) 7 (12)
M2 16 (27) 22 (36)
M4 10 (17) 7 (12)
M5 14 (24) 13 (21)
M6 1 (2) 1 (2)
M7 6 (10) 4 (7)
Other and missing 2 (3) 3 (5)
CD33 expression .07
Positive 50 (85) 59 (97)
Negative 7 (12) 2 (3)
No data 2 (3) 0
CNS disease .55
Yes 7 (12) 6 (10)
No 51 (86) 55 (90)
Data missing 1 (2) 0 (0)
Cytogenetics .93
Normal karyotype 11 (19) 9 (15)
t(8;21) 13 (22) 14 (23)
inv(16) 4 (7) 6 (10)
t(9;11) 10 (17) 8 (13)
11q23 non t(9;11) 6 (10) 5 (8)
Other aberrations 15 (25) 19 (31)
FLT3 aberrations .23
ITD 0 (0) 4 (7)
ALM (D835/I836) 4 (7) 4 (7)
Wild type 41 (70) 37 (61)
Not tested 14 (24) 16 (26)
Risk group .69
Standard risk 54 (92) 57 (93)
High risk 5 (8) 4 (7)
Remission achieved .22
After first induction 44 (75) 51 (84)
After second induction 15 (25) 10 (16)
GO indicates gemtuzumab ozogamicin; FAB, French-American-British; ITD,
internal tandem duplication; and ALM, activation loop mutation.
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After relapse, second complete remission (CR2) was achieved
in 44 (90%), 88% in the GO arm, and 92% in those who were
randomized to no further therapy. HSCT was performed in 42 of
the 44 patients who achieved CR2 and the 2 patients with t-MDS.
The median time from last GO to HSCT was 405 days (range
47-866). No patients had signs of VOD after HSCT.
The 5-year EFS and OS was 55% (95% confidence interval
[CI]: 51-59) versus 51% (95% CI: 42-59; nonsignificant) and
74% (95% CI: 70-78) versus 80% (95% CI: 72-86; nonsignificant)
in those randomized to receive GO versus no further therapy,
respectively (Figures 3 and 4). EFS was analyzed according to
randomization by sex, age, WBC, French-American-British (FAB),
CD33 positivity, cytogenetics, and response to induction (Table 4).
There were no significant differences between EFS according to
GO randomization in any of the subgroups analyzed.
The 3-year survival after relapse was 43% without significant
difference between the 2 randomized arms (Figure 5). Deaths
occurred in 24: in 18 from progressive disease (in 12 after HSCT in
CR2) and in 6 from HSCT-related complications, mostly infections
(Figure 5).
Table 2. Hematologic and hepatic toxicity in 53 patients who received 2 courses of GO after randomization
GO1 baseline GO1 nadir GO1 peak GO2 baseline GO2 nadir GO2 peak
Hematologic
Hb, g/dL 10.5 10.1 12.0 10.8
8.1-14.3 7.8-14.0 9.8-15.0 8.2-14.8
WHO grade 3/4 (%) 2/0 (4) 0/0 (0)
WBC,109/L 2.7 0.5 3.7 0.7
1.5-9.8 0.0-4.1 1.6-16.8 0.2-4.4
WHO grade 3/4 (%) 7/43 (94) 13/35 (92)
Neutrophils,109/L 1.3 0.0 1.6 0.0
0.7-8.6 0.0-3.2 0.4-13.3 0.0-1.4
WHO grade 3/4 (%) 0/50 (96) 1/47 (96)
Platelets,109/L 199 83 238 62
43-470 10-239 97-460 11-202
WHO grade 3/4 (%) 5/3 (15) 16/4 (39)
Hepatic
ALAT, U/L 48 82 61 72
14-204 20-279 12-121 21-282
WHO grade 3/4 (%) 2/0 (4) 1/0 (2)
Bilirubin, mol/L 5 8 5 7
2-15 2-28 1-15 2-36
WHO grade 3/4 (%) 0/0 (0) 0/0 (0)
Median values and ranges with WHO toxicity grade 3 and 4 are presented.
GO indicates gemtuzumab ozogamicin; Hb, hemoglobin; and ALAT, alanine aminotransferase.
Table 3. Follow-up of the 120 patients randomized
Characteristics
Randomized to GO,
N  59, n (%)
Randomized to no
further therapy,
N  61, n (%)
Treated with GO
No 5 (8) 60 (98)
1 course 1 (2) 0
2 courses 53 (90) 1 (2)
Events
No event 33 (56) 35 (57)
Death in CR1 0 (0) 1 (2)
MDS 2 (3) 0 (0)
Relapse 24 (41) 25 (41)
Median time from diagnosis to
relapse, mo
16 11
Median follow-up for patients
alive, y
4.3 4.1
HSCT in CR2
Yes 23* 21
Median days from last
consolidation to SCT
458 286
Survival
5-year EFS, % 55 51
95% confidence interval, % 51-59 42-59
5-year OS, % 74 80
95% confidence interval, % 70-78 72-86
GO indicates gemtuzumab ozogamicin; CR1, first complete remission; MDS,
myelodysplastic syndrome; HSCT, hematopoietic stem cell transplantation; EFS,
event-free survival; and OS, overall survival.
*Including 2 patients with therapy-related MDS. Figure 3. EFS in patients randomized to GO versus no further therapy (no GO).
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Discussion
The overall results of NOPHO-AML 2004 are favorable with a
high remission rate and OS around 70%3 but the high relapse rate
remains a problem. GO given after consolidation postponed the
relapses a median of 5 months but it did not change the cumulated
rate of relapse. The delay of the relapses in the GO arm was not
statistically significant and could be a chance finding. The late
relapses did not translate into a superior survival as would be
expected because time of relapse is the most important prognostic
factor in relapsed AML.16,17
The randomized study of 6-mercaptopurine and cytarabine
maintenance therapy by the French LAME (Leucemie Aigue
Myeloblastique Enfant) group documented that those who relapsed
after maintenance were more refractory to reinduction resulting in a
poorer outcome after relapse.18 Similar results were observed after
thioguanine, vincristine, azacitidine, cytarabine, and cyclophos-
phamide maintenance reported by the Children’s Cancer Groups
(CCG).19 In contrast, reinduction in the present study was success-
ful with a CR2 rate of 90% without any increased risk of refractory
relapsed AML in patients previously treated with GO and no
difference between survival in the 2 groups. A relatively large
fraction of the relapsed patients (17 of 49, 35%) had core-binding
factor (CBF) AML contribution to the high CR2 rate.
GO during induction seems to be especially beneficial for adult
patients with t(8;21)(q22;q22) or inv(16)(p13q22) AML.6 Patients
with t(8;21) had a high relapse rate in the NOPHO-AML 2004 study
which was not influenced by the addition of GO therapy after
consolidation. Patients with poor response also had a high relapse rate
that was not influenced by GO therapy. In contrast, young children and
those with MLL aberration had a very favorable EFS regardless of GO
therapy.
The addition of GO to induction chemotherapy does not change
the remission rate but reduces the relapse rate and increases
survival in adults.6,20 We did not find any benefit giving GO as a
postconsolidation therapy, and similar results are reported in
adults,14 suggesting that only early GO therapy may prevent
relapse. An additional fifth course of chemotherapy does not
improve the relapse-free survival,4 indicating that only the first
months of therapy predict the relapse rate.
High expression of CD33 is associated with adverse disease
features and is an independent predictor of inferior outcome in
pediatric AML.21 However, the correlation between CD33 expres-
sion and response to GO is still under debate. We did not find any
trend toward different EFS in those who were CD33 positive versus
negative but we did not perform quantitative studies of CD33
expression. Antigen change from diagnosis to relapse is common in
Figure 5. Survival after relapse in patients randomized to gemtuzumab ozogami-
cin (GO) versus no further therapy (no GO).
Figure 4. Overall survival in patients randomized to GO versus no further
therapy (no GO).
Table 4. Five-year EFS in subgroups with 10 or more patients
according to the result of randomization
Characteristics
Randomized to
GO EFS, %
Randomized to no
further therapy
EFS, % P
Sex
Male 42 46 .5
Female 68 57 .5
Age, y
0-1 74 80 .8
2-9 51 36 .3
10 42 50 .3
White blood count, 109/L
0-9.9 44 47 .7
10 61 53 .7
FAB classification
M1/M2 28 32 .5
M4/M5 70 71 .8
Cytogenetics
Normal karyotype 53 44 .4
t(8;21) or inv(16) 38 50 .9
11q23 68 62 .9
Other aberrations 59 49 .9
Remission achieved
After first induction 66 59 .7
After second induction 11 17 .4
GO indicates gemtuzumab ozogamicin; EFS, event-free survival; and FAB,
French-American-British.
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pediatric AML but the expression of CD33 is stable with changes in
only 2% of the patients.22 Although we do not have data on CD33
status at relapse, it seems unlikely that a shift in CD33 expression is
the cause of the failure of GO to prevent relapse in this trial.
Therapy-related MDS occurred in 2 patients treated with GO.
Second malignant neoplasms are rare in pediatric AML with a
15-year cumulated incidence of less than 2%.23,24 GO is not known
to be associated with secondary malignancies and our observation
may be a chance finding.
The most common acute side effect of GO was severe
neutropenia seen in 96%. Febrile neutropenia occurred in 40%,
similar to the frequency in children with relapsed AML.11 There
was a strong association between fever after the first course and the
risk of febrile neutropenia after the second course. The median time
to neutrophil recovery was 15 days which is a little shorter than the
20 days observed in elderly AML patients receiving 3 cycles of
postremission therapy with 6 mg/m2 of GO.14
Platelet transfusions were given to 45% of older patients
receiving GO14 but only to 17% in our cohort and only 27% of the
courses were followed by platelet nadir below 50. Significantly
more patients had platelet nadir  50 after the second course than
after the first course (39% vs 15%).
Hemoglobin was barely affected by the GO therapy. The
syndrome of toxic symptoms during intravascular hemolysis and
impaired hemoglobin scavenging described in children with re-
lapsed AML treated with GO25 was not observed in any of the
patients.
No patients had hyperbilirubinemia above 40 mol/L or VOD
in contrast to the 23% with grade 3 or 4 liver toxicity in adults.26,27
A high rate of VOD has primarily been reported when GO was
given after HSCT.28 Treatment with GO in heavily pretreated
children with relapsed AML has been with manageable toxicity,
including VOD in only 1 of 15.29 The risk of VOD seems to be
increased with concomitant use of thioguanine,30 and when GO is
followed by HSCT within 3 months.31,32 All our patients re-
ceived thioguanine as part of induction but more than 6 months
before GO. None of the patients who received transplants after
GO (at a median interval of 405 days from second GO) showed
signs of VOD.
The toxicity profile for GO used as monotherapy in this
postconsolidation setting in heavily pretreated children with AML
is favorable, but the lack of improvements in the final survival
indicates little if any role of GO in the postconsolidation phase of
AML therapy.
Our patients were all in CR1 with a low CD33-antigen load in
peripheral blood which is associated with complete GO saturation
of the CD33 cells and an efficient bone marrow cell kill.33 GO
might have had some effect as indicated by the nonsignificant
postponing of the relapses. Although alternative schedules of GO
may have produced different results, postconsolidation mono-
therapy with GO does not, despite the good tolerability, seem a
promising tool for preventing relapse.
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